Introduction {#s1}
============

In the management of outpatients, reducing the risk of cardiovascular event is based mainly on addressing traditional cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking habits. However, although these risk factors are important, they do not explain every cardiovascular event \[[@R01]-[@R03]\]. It is therefore important to explore novel biomarkers of cardiovascular diseases.

The impairment of hemorheology is considered to be a further important factor in the incidence of cardiovascular events, in addition to atherosclerosis \[[@R04], [@R05]\]. In recent years, a commercial device to evaluate hemorheology using microscopic images, the microchannel array flow analyzer (MC-FAN), has been introduced to the clinical setting \[[@R06]\]. The MC-FAN is simple and is superior to other methods of hemorheological evaluation in terms of the accuracy of channel dimensions and high reproducibility. MC-FAN can be used to measure the whole blood passage time (WBPT). Cross-sectional studies have reported significant relationships between an increase in WBPT and cardiovascular risk factors or cardiovascular disease \[[@R07]-[@R10]\]. However, there have been no prospective studies of the clinical usefulness of WBPT as a predictor of cardiovascular events. The aim of this prospective study was therefore to assess the efficacy of WBPT evaluated by the MC-FAN as a predictor of primary cardiovascular events in patients with traditional cardiovascular risk factors.

Materials and Methods {#s2}
=====================

Participants {#s2a}
------------

Between January 2008 and December 2009, 1,134 outpatients (696 women (61.4%) and 438 men (38.6%)) with traditional cardiovascular risk factors but no history of cardiovascular events were prospectively enrolled at the Hitsumoto Medical Clinic, Yamaguchi, Japan. The mean (± standard deviation) age was 67 ± 11 years. WBPT was measured as described below and the participants were assigned accordingly to one of three groups: L (low, WBPT \< 50 s; n = 499), M (medium, WBPT = 50 - 70 s; n = 295), or H (high, WBPT \> 70 s; n = 340). The study protocol was approved by Local Ethics Committee of Hitsumoto Medical Clinic and informed consent was obtained from all the participants.

Evaluation of hemorheology using an MC-FAN {#s2b}
------------------------------------------

The participant's hemorheology was evaluated by measuring WBPT using an MC-FAN HR300 rheometer (MC Healthcare Inc., Tokyo), as previously described \[[@R06], [@R08]\]. Briefly, the microchannel passage time for 100 µL of physiologic saline was first measured as a control. Then, the same measurement was determined for blood obtained from the participant with 100 µL of the heparinization sample. The WBPT was corrected for the passage time of the physiologic saline, SPT, as WBPT × 12/SPT. The flow of blood cells through individual microchannels was observed and recorded using an inverted metallographic microscope, video camera, and video recorder. The width, length, and depth of the microchannel formation were 7, 30, and 4.5 µm, respectively. Examination was performed within 60 min of blood sampling. The inter- and intra-assay coefficients of variation for WBPT were 8% and 5%, respectively.

Evaluation of clinical parameters {#s2c}
---------------------------------

The participant's body mass index was calculated as the weight in kilograms divided by the square of the height in meters; obesity was defined by the Japanese criteria of body mass index ≥ 25 kg/m^2^. Current smoking was defined as smoking at least one cigarette per day during the previous 28 days. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or the use of anti-hypertensive medication. Dyslipidemia was defined as a low-density lipoprotein cholesterol level ≥ 140 mg/dL, a high-density lipoprotein cholesterol level ≤ 40 mg/dL, a triglyceride level ≥ 150 mg/dL, or the use of anti-dyslipidemic medication. Diabetes mellitus was defined as a fasting blood glucose level ≥ 126 mg/dL or the use of anti-diabetic medication. The following blood parameters were measured: blood cell counts, plasma glucose, serum lipid concentrations, and serum high-sensitivity C-reactive protein (hs-CRP) concentration. Blood samples were collected from the antecubital vein in the morning after 12 h of fasting. Total cholesterol and triglyceride concentrations were measured using standard enzymatic methods. High- and low-density lipoprotein cholesterol concentrations were measured using selective inhibition and Friedewald's formula, respectively \[[@R11]\]. Participants with a serum triglyceride concentration ≥ 400 mg/dL were excluded from the analysis, considering the accuracy of this method. Glucose concentrations were measured by the glucose oxidase method. The hs-CRP concentration was measured using high-sensitivity latex-enhanced immunonephelometry. As a physiological marker of arterial function, the cardio-ankle vascular index (CAVI) was measured using a VaSera CAVI system (Fukuda Denshi), as described previously \[[@R12]\]. Briefly, brachial and ankle pulse waves were determined using inflatable cuffs, with the pressure maintained between 30 and 50 mm Hg to ensure that the cuff pressure exerted minimal effects on systemic hemodynamics. Of note, systemic blood and pulse pressures were simultaneously determined with the participants in the supine position. CAVI was measured after a 10-min rest in a quiet room. The value used for CAVI was the mean of the values for the left and right sides.

Follow-up {#s2d}
---------

For this study, the follow-up period terminated in January 2018. The endpoint for this study was a major adverse cardiovascular event (MACE), a composite of cardiovascular death, non-fetal myocardial infarction, and non-fetal ischemic stroke. The median follow-up period to determine the incidence of MACE was 81.9 months (range, 4 - 120 months).

Statistical analysis {#s2e}
--------------------

Data were analyzed using Stat View-J 5.0 (HULINKS, Tokyo, Japan) and MedCalc for Windows version 14.8.1 (MedCalc Software, Ostend, Belgium). Data are presented as mean ± standard deviation. One-way analysis of variance (ANOVA) and the Kruskal-Wallis test were used for comparisons of the three groups. Post-hoc testing was performed using Fisher's protected least significant differences or the Mann-Whitney U-test with the Bonferroni correction. Event-free survival rate curves were plotted using Kaplan-Meier analysis and the differences between the curves were evaluated using the long-rank test. Multivariate analysis was performed using multivariate Cox regression analysis. Receiver operating characteristic (ROC) curves were constructed and the Youden Index was used to determine the optimal cut-off for WBPT for predicting the participants who experienced a MACE. P \< 0.05 was considered statistically significant.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} presents the characteristics of the participants at registration. The mean WBPT for groups L, M, and H were 40.3, 59.6, and 79.4 s, respectively. The following factors were significantly higher in H than in M or L: the proportions of men, current smokers, and participants with diabetes mellitus, and the mean hematocrit, fasting blood glucose concentration, hs-CRP concentration, and CAVI values. [Figure 1](#F1){ref-type="fig"} shows the Kaplan-Meier curve for the incidence of MACE. The median follow-up period was 81.9 months. During follow-up, 95 participants experienced at least one MACE (L, 21 participants (4.2%); M, 24 participants (8.1%); H, 50 participants (14.7%)). The Kaplan-Meier curve confirmed that group H had a higher incidence of MACE compared to groups M and L (log-rank test, P \< 0.001). [Table 2](#T2){ref-type="table"} presents the clinical parameters at registration of all the participants, comparing those who experienced MACEs with those who did not. Male sex, age, current smoking status, systolic blood pressure, the presence of diabetes mellitus, fasting blood glucose concentration, hs-CRP concentration, and CAVI were considerably higher in participants who experienced MACE than in those who did not, and levels of renin-angiotensin system (RAS) inhibitor and statin use were considerably lower. [Table 3](#T3){ref-type="table"} presents the results of the multivariate Cox regression analysis for the MACE. The 10 variables were selected as being significant factors for MACE in the univariate analysis or check of multicollinearity among variables. Of these, seven variables (CAVI, being in group H, male sex, age, the presence of diabetes mellitus, hs-CRP concentration, and statin use) exhibited a considerable hazard ratio (HR) for MACE. [Figure 2](#F2){ref-type="fig"} shows the ROC curve analysis for the incidence of MACE based on WBPT. A cut-off value for WBPT of 72.4 s yielded the largest area under the curve of 0.705 (95% confidence interval (CI): 0.678 - 0.732), with a sensitivity of 51.7% and specificity of 85.4% for discriminating between the participants who did and did not experience MACE during the follow-up period. To assess the clinical efficacy of a combination of the biomarkers for hemorheology and arterial function, the participants were divided into four groups according to cut-off levels of WBPT = 72.4 s and CAVI = 9, and a multivariate Cox regression analysis was performed ([Fig. 3](#F3){ref-type="fig"}). Having values above the cut-off for one of these factors (WBPT \> 73.4 s or CAVI \> 9) was associated with significantly higher HRs for MACE (HR: 3.18, 95% CI: 1.29 - 7.44, P \< 0.01; HR: 3.36, 95% CI: 1.31 - 7.60, P \< 0.01, respectively) than having values below these cut-offs. The HR was higher still when both factors were above the cut-off levels (HR, 10.62; 95% CI, 5.38 - 21.31; P \< 0.001) compared with both factors being below the cut-offs.

###### Characteristics of Patients

                                 Overall           Group L         Group M          Group H                 P value
  ------------------------------ ----------------- --------------- ---------------- ----------------------- ----------
  N (male/female)                1,134 (438/696)   499 (168/331)   295 (111/184)    340 (159/181)^\*\#\#^   \< 0.001
  Age (yrs)                      67 ± 11           66 ± 11         67 ± 11          67 ± 11                 0.136
  WBPT (s)                       57.0 ± 17.8       40.3 ± 5.2      59.6 ± 5.9       79.4 ± 8.5\*^\#^        \< 0.001
  Risk factors                                                                                              
    Obesity, n (%)               366 (32)          137 (27)        103 (35)\*\*\*   126 (37)\*\*            \< 0.01
    Current smoker, n (%)        227 (20)          57 (11)         56 (19) \*\*     114 (34)^\*\#^          \< 0.001
    Hypertension, n (%)          844 (74)          367 (74)        215 (73)         262 (77)                0.405
    SBP(mm Hg)                   140 ± 13          139 ± 11        141 ± 9          141 ± 17                0.139
    DBP (mm Hg)                  88 ± 16           87 ± 10         89 ± 10          89 ± 25                 0.108
    Dyslipidemia, n (%)          805 (71)          356 (71)        207 (70)         242 (71)                0.936
    Diabetes mellitus, n (%)     282 (25)          105 (21)        71 (24)          106 (31)\*^\#\#^        \< 0.01
  Blood findings                                                                                            
    Hematocrit (%)               40 ± 5            39 ± 4          40 ± 5           41 ± 5\*^\#\#^          \< 0.001
    White blood cell (/µL)       6,645 ± 1,495     6,535 ± 1,514   6,650 ± 1,463    6,801 ± 1,486           0.501
    Platelet count (×10^4^/µL)   21 ± 5            21 ± 4          22 ± 5           21 ± 5                  0.86
    Total cholesterol (mg/dL)    223 ± 39          223 ± 40        220 ± 38         223 ± 40                0.157
    LDL cholesterol (mg/dL)      146 ± 36          148 ± 37        144 ± 37         144 ± 35                0.103
    Triglyceride (mg/dL)         125 ± 66          122 ± 66        122 ± 67         131 ± 64                0.098
    HDL cholesterol (mg/dL)      52 ± 13           52 ± 13         51 ± 14          53 ± 13                 0.546
    FBG (mg/dL)                  114 ± 27          111 ± 27        112 ± 26         119 ± 29\*^\#^          \< 0.001
    Log-hs-CRP (mg/dL)           -1.3 ± 0.5        -1.5 ± 0.4      -1.4 ± 0.6       -1.0 ± 0.4\*^\#^        \< 0.001
    CAVI                         9.0 ± 1.2         8.8 ± 1.2       9.0 ± 1.2        9.4 ± 1.2^\*\#^         \< 0.001
  Medication                                                                                                
    RAS inhibitor, n (%)         418 (37)          190 (38)        115 (39)         113 (33)                0.454
    Statin, n (%)                335 (30)          145 (29)        91 (31)          99 (29)                 0.68
    Anti-diabetic drugs, n (%)   236 (21)          97 (19)         51 (17)          88 (26)                 0.174

Continuous values are mean ± SD. WBPT: whole blood passage time; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; FBG: fasting blood glucose; hs-CRP: high sensitivity C reactive protein; CAVI: cardio-ankle vascular index; RAS: renin-angiotensin system. \*P \< 0.001 vs. group L, \*\*P \< 0.01 vs. group L, \*\*\*P \< 0.05 vs. group L, ^\#^P \< 0.001 vs. group M, ^\#\#^P \< 0.05 vs. group M.

![Kaplan-Meier curve for the incidence of major adverse cardiovascular events. The Kaplan-Meier curve confirmed that group H had a higher incidence of major adverse cardiovascular events compared to groups M and L (log-rank test, P \< 0.001).](cr-09-231-g001){#F1}

###### Clinical Parameters at Registration of Patients With and Without Major Adverse Cardiovascular Event

                               MACE (-)          MACE (+)        P value
  ---------------------------- ----------------- --------------- ----------
  N (male/female)              1,039 (385/654)   95 (53/42)      \< 0.001
  Age (yrs)                    66 ± 11           70 ± 9          \< 0.01
  Obesity, n (%)               329 (32)          37 (39)         0.146
  Current smoker, n (%)        197 (19)          30 (32)         \< 0.01
  Hypertension, n (%)          772 (74)          72 (76)         0.751
  SBP (mm Hg)                  139 ± 13          146 ± 16        \< 0.05
  DBP (mm Hg)                  88 ± 17           86 ± 11         0.286
  Dyslipidemia, n (%)          738 (71)          67 (71)         0.918
  Diabetes mellitus, n (%)     242 (23)          40 (42)         \< 0.001
  Hematocrit (%)               40 ± 5            41 ± 5          0.640
  White blood cell (/µL)       6,624 ± 1,492     6,884 ± 1,484   0.102
  Platelet count (×10^4^/µL)   21 ± 5            22 ± 5          0.463
  Total cholesterol (mg/dL)    222 ± 39          223 ± 44        0.938
  LDL cholesterol (mg/dL)      143 ± 35          147 ± 42        0.384
  Triglyceride (mg/dL)         125 ± 66          125 ± 64        0.509
  HDL cholesterol (mg/dL)      52 ± 13           50 ± 13         0.146
  FBG (mg/dL)                  113 ± 27          121 ± 27        \< 0.05
  Log-hs-CRP (mg/dL)           -1.3 ± 0.6        -1.1 ± 0.5      \< 0.001
  CAVI                         9.0 ± 1.2         9.9 ± 1.1       \< 0.001
  RAS inhibitor, n (%)         393 (38)          25 (26)         \< 0.05
  Statin, n (%)                318 (31)          17 (18)         \< 0.01
  Anti-diabetic drug, n (%)    210 (20)          26 (27)         0.100

Continuous values are mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; FBG: fasting blood glucose; hs-CRP: high sensitivity C reactive protein; CAVI: cardio-ankle vascular index; RAS: renin-angiotensin system.

###### Multivariate Cox Regression Analysis for Major Adverse Cardiovascular Event

  HR                             95% CI        P value
  ----------------------- ------ ------------- ---------
  CAVI (\> 9)             2.52   1.35 - 3.53   \< 0.01
  Group H (vs. group L)   2.32   1.31 - 3.20   \< 0.01
  Sex (male)              2.05   1.30 - 3.13   \< 0.01
  Age (≥ 65 yrs)          1.87   1.15 - 3.07   \< 0.01
  Diabetes mellitus       1.69   1.11 - 2.57   \< 0.05
  hs-CRP (≥ 0.1mg/dL)     1.45   1.04 - 2.22   \< 0.05
  Statin                  0.67   0.33 - 0.92   \< 0.05
  Current smoker          1.38   0.98 - 2.01   0.065
  RAS inhibitor           0.66   0.42 - 1.04   0.073
  SBP (≥ 140mm Hg)        1.23   0.80 - 1.91   0.339

HR: hazard ratio; CI: confidence interval; CAVI: cardio-ankle vascular index; hs-CRP: high sensitivity C reactive protein; RAS: renin-angiotensin system; SBP: systolic blood pressure.

![Prediction of major adverse cardiovascular events at follow-up period using WBPT. A WBPT cut-off of 72.4 s yielded the largest area under the curve of 0.705 (95% confidence interval: 0.678 - 0.732), with a sensitivity of 51.7% and specificity of 85.4% for discriminating between those who did and did not experience major adverse cardiovascular events during the follow-up period. WBPT: whole blood passage time.](cr-09-231-g002){#F2}

![Multivariate Cox regression analysis for major adverse cardiovascular events using a combination of the WBPT and CAVI. The participants were divided into four groups according to cut-off levels of WBPT = 72.4 s and CAVI = 9, and a multivariate Cox regression analysis was performed. Having values above the cut-off for one of these factors (WBPT \> 73.4 s or CAVI \> 9) was associated with significantly higher HRs for major adverse cardiovascular events (HR: 3.18, 95% CI: 1.29 - 7.44, P \< 0.01; HR: 3.36, 95% CI: 1.31 - 7.60, P \< 0.01, respectively) than having values below these cut-offs. The HR was higher still when both factors were above the cut-off levels (HR, 10.62; 95% CI, 5.38 - 21.31; P \< 0.001) compared with both factors being below the cut-offs. Adjustment factors are sex, age, diabetes mellitus, hs-CRP, and statin use. \*P \< 0.01 vs. patients with WBPT as ≤ 72.4 s and CAVI as ≤ 9; \*\*P \< 0.001 vs. patients with WBPT as ≤ 72.4 s and CAVI as ≤ 9. WBPT: whole blood passage time; CAVI: cardio-ankle vascular index; HR: hazard ratio, CI: confidence interval; hs-CRP: high sensitivity C reactive protein.](cr-09-231-g003){#F3}

Discussion {#s4}
==========

Previous studies have reported relationships between the incidence of cardiovascular disease and traditional risk factors such as male sex, aging, and diabetes mellitus \[[@R13]-[@R15]\]. Consistent with these previous findings, the results of the present study found these factors to be independent predictors for MACE. In addition, this study found that high WBPT was a further independent predictor for MACE. WBPT showed significant associations with smoking habits, hs-CRP concentration, and CAVI. The study also indicated the clinical efficacy of using a combination of the WBPT and CAVI as a predictor for MACE.

Several cross-sectional studies have assessed WBPT in healthy populations or in patients with cardiovascular risk factors, with the results suggesting that the cut-off value for cardiovascular risk is 50 - 70 s \[[@R10], [@R16]-[@R18]\]. Based on these previous results, the present study prospectively divided the participants into three groups according to two simple cut-off levels of 50 s and 70 s. The results showed that participants with WBPT \> 70 s were a population at high risk of primary cardiovascular events. In the ROC analysis, a WBPT cut-off of 72.4 s yielded the largest area under the curve of 0.705 for discriminating between those who did and did not experience MACE during the follow-up period. Thus, for primary cardiovascular disease prevention, we perform examinations or intervention therapy for any patients with WBPT exceeding approximately 70 s.

There are several possible mechanisms to explain why smoking affects hemorheology, such as platelet activation, an increase in leukocyte adhesion ability, and elevation of plasma viscosity \[[@R19], [@R20]\]. There have been several clinical studies of the relationship between smoking habits and WBPT \[[@R08], [@R16], [@R18], [@R21]\]. Shimada et al. reported a positive correlation between WBPT and the daily consumption of tobacco or the Brinkman index, and three months of smoking cessation significantly reduced WBPT \[[@R21]\]. In contrast, in this study the prevalence of smoking increased with an increase in WBPT. Even though a smoking habit was not found to be an independent predictor for MACE in this study, the results of this and previous studies have indicated that smoking cessation is strongly recommended to improve hemorheology.

Hs-CRP is used as a marker of inflammation, and several epidemiological studies have indicated that a high hs-CRP level is a predictor of cardiovascular disease \[[@R22], [@R23]\]. The results of the present study also found that high hs-CRP (≥ 0.1 mg/dL) was an independent predictor for MACE in patients with traditional cardiovascular risk factors. One explanation for hs-CRP level being a cardiovascular risk factor is thought to be chronic inflammation in the arterial walls, which contributes to the development of atherosclerosis, including plaque instability \[[@R24]-[@R26]\]. Several mechanisms by which inflammation causes impairment of blood rheology have been proposed, including platelet aggregation and the elevation of plasma viscosity \[[@R27], [@R28]\]. In this study, the hs-CRP levels were significantly higher in group H than in groups M and L. RAS inhibitors and statins have been reported to reduce inflammation *in vivo* \[[@R29]-[@R31]\], with a reported reduction in the incidence of primary cardiovascular events \[[@R32], [@R33]\]. However, the use of medications such as RAS inhibitors or statins was approximately 30% degree in group H. Positively using such drugs with anti-inflammatory effects for patients with high hs-CRP concentration, especially those with high WBPT, may help reduce the incidence of cardiovascular.

CAVI provides a novel marker of systemic arterial stiffness that is independently associated with blood pressure \[[@R12]\]. A number of studies have reported the clinical usefulness of CAVI as a cardiovascular risk factor \[[@R34]-[@R36]\]. In the present study, CAVI \> 9 was one of the strongest predictors of MACE of all the explanatory variables. In addition, CAVI levels were higher in the participants with higher WBPT values. There have been several reports of a significant relationship between WBPT and physiological markers of arterial stiffness \[[@R37], [@R38]\]. In addition, a study has reported a significant relationship between WBPT and endothelial dysfunction \[[@R39]\], and Endo et al reported that CAVI reflected endothelial dysfunction as estimated by brachial artery flow-mediated vasodilatation \[[@R40]\]. Thus, the results of this and previous studies suggest that impaired hemorheology affected arterial function such as arterial stiffness or endothelial dysfunction, thereby increasing the incidence of cardiovascular disease.

To evaluate the clinical efficacy of using a combination of hemorheology and arterial function biomarkers, the participants of this study were divided into four groups based on the cut-off values of WBPT = 72.4 s and CAVI = 9 and a multivariate analysis was performed. The HR for experiencing a MACE with both high WBPT and high CAVI compared with both low WBPT and low CAVI was approximately 3 points higher than the HR for either high WBPT or high CAVI but not both. Thus, the participants with high WBPT and CAVI were considered to be a high-risk population for primary cardiovascular events. Previous studies have shown that lifestyle or medical interventions affected both hemorheology and arterial function \[[@R08], [@R21], [@R41]-[@R46]\], and the methods for measuring WBPT and CAVI are simple and take little time in clinical practice. We therefore check these two markers in our patients and administer intervention therapy such as lifestyle modification or medication for those with high WBPT and CAVI. In this way, we expect to efficiently reduce primary cardiovascular events in patients with traditional cardiovascular risk factors.

Limitations {#s4a}
-----------

This study had several limitations. First, it was conducted at a single center and its findings cannot be generalized to all medical centers. Second, WBPT was measured only once, at registration. A further investigation of the association between serial changes in WBPT and primary cardiovascular events is needed. Finally, further studies concerning patients with high WBPT and traditional cardiovascular risk factors are warranted to determine whether aggressive intervention therapy, such as lifestyle modification or medication, reduces the incidence of primary cardiovascular events.

Conclusions {#s4b}
-----------

This study demonstrated that WBPT evaluated by MC-FAN as a marker of hemorheology was a predictor of primary cardiovascular events in patients with traditional cardiovascular risk factors. The predictive value for the incidence of cardiovascular events was increased by using a combination of WBPT and CAVI as a marker of arterial function.
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